このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

TARSILA リアルワールドエビデンス研究 (TARSILA)

2026年11月2日 更新者:Maicon Falavigna、Inova Medical

ブラジルにおける乳児のRSV関連急性呼吸器疾患に対する母体RSVpreFワクチンの実世界における有効性(TARSILA研究):多施設共同、前向き、テスト陰性、症例対照研究

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.

研究の種類

観察的

入学 (推定)

5000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Paraná
      • Cascavel、Paraná、ブラジル、85818-130
        • 募集
        • Unidade de Pronto Atendimento Veneza
        • コンタクト:
      • Curitiba、Paraná、ブラジル、80060-900
        • 募集
        • Complexo do Hospital de Clínicas da Universidade Federal do Paraná
        • コンタクト:
        • 主任研究者:
          • Cristina de Oliveira Rodrigues
      • Curitiba、Paraná、ブラジル、80240-031
        • 募集
        • Hospital Infantil Pequeno Príncipe
        • コンタクト:
        • 主任研究者:
          • Heloisa Ihle Garcia Giamberardino
      • Marechal Cândido Rondon、Paraná、ブラジル、85960-000
        • 募集
        • Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
        • コンタクト:
      • Palotina、Paraná、ブラジル、85950-000
        • 募集
        • Unidade de Saúde Central de Palotina
        • コンタクト:
      • Toledo、Paraná、ブラジル、85902-480
        • 募集
        • Unidade de Pronto Atendimento II de Toledo
        • コンタクト:
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、ブラジル、91350-200
        • 募集
        • Hospital Nossa Senhora da Conceição
        • コンタクト:
        • 主任研究者:
          • Fernanda H Varela
      • Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
        • 募集
        • Hospital de Clínicas de Porto Alegre
        • コンタクト:
        • 主任研究者:
          • Ricardo Becker Feijó

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

11ヶ月歳未満 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Infants with acute respiratory illness (ARI)

説明

Tarsila Inpatient Study

Inclusion Criteria

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Maternal or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Infant previously enrolled in this study.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.

Tarsila Outpatient Study

Inclusion Criteria:

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Mother or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.
  • Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_CONTROL
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Cases

Infants with a positive respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Controls

Infants with a negative respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing).

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
時間枠:Occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Occurring ≤180 days after birth.

二次結果の測定

結果測定
メジャーの説明
時間枠
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) .

Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
時間枠:ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness.

ARI occurring ≤180 days after birth

その他の成果指標

結果測定
メジャーの説明
時間枠
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization

RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization.

Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) .

Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.

RT-qPCR-confirmed RSV-positive LRTD in-hospital death.

Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization.

Hospitalization occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
時間枠:Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed HMPV-positive LRTD hospitalization

Hospitalization occurring ≤180 days after birth
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
時間枠:ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
ARI occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
時間枠:ARI occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness.

ARI occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
時間枠:LRTD occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤180 days after birth.
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
時間枠:LRTD occurring ≤360 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤360 days after birth.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Maicon Falavigna、Inova Medical

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月27日

一次修了 (推定)

2028年9月30日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年2月20日

QC基準を満たした最初の提出物

2026年2月25日

最初の投稿 (実際)

2026年3月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CAAE 95166426.7.1001.0008

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。